BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...


Embrex, now a part of Zoetis (NYSE: ZTS), a global animal health company, developed and launched the world’s first commercial in ovo vaccination device more than 20 years ago. Its Inovoject® System is considered to be the industry standard for in ovo technology, revolutionized automation in the hatchery. Pfizer’s animal health division acquired Embrex in 2007.
Website